Human milk oligosaccharides (HMOs) are prebiotics found in human milk that support digestive, immune and cognitive health in infants. While not directly digested, HMOs are metabolized by beneficial gut bacteria, such as some Bifidobacterium species, thus shaping the evolving infant gut microbiota.
Research indicates that commercially produced HMOs can mimic some of the health-promoting effects of the HMOs present in human milk, enabling the creation of infant formula that is closer to human milk than ever before.
In addition, DuPont Nutrition & Health is uncovering ways in which the health-promoting benefits of HMOs can be utilized in dietary supplements, extending the advantages of HMOs across the population.
In her presentation, Dr. Maukonen reveals key findings from studies that investigate the impact and benefits of HMOs, with a focus on 2’-fucosyllactose (2’-FL), the most abundant HMO found in human milk.
Ratna Mukherjea, technology and innovation leader for HMO, DuPont Nutrition & Health, will join Dr. Maukonen to answer questions following the presentation.